Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965866 | 0.90 | KDM4E (0.39) | AURKAKDM4ERAB9ANPC1LMNA | |
| SCHEMBL968016 | 0.83 | CALCA (0.39) | KDM4ERAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL966356 | 0.81 | LMNA (0.41) | RAB9ANPC1LMNAALDH1A1GAA | |
| SCHEMBL967981 | 0.80 | PRMT5 (0.37) | RAB9ANPC1RIPK1SMN1; SMN2 | |
| SCHEMBL965725 | 0.79 | RAB9A (0.37) | RAB9ANPC1KDRRIPK1SMN1; SMN2 | |
| SCHEMBL966266 | 0.77 | ALDH1A1 (0.45) | KDM4EKDRMDM2ALDH1A1GAA | |
| SCHEMBL967522 | 0.77 | ACHE (0.42) | KDM4ERAB9ALMNAELANEALDH1A1 | |
| SCHEMBL969722 | 0.76 | RAB9A (0.45) | KDM4ERAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL967173 | 0.76 | ATR (0.39) | AURKAKDM4ERAB9ANPC1LMNA | |
| SCHEMBL967148 | 0.76 | ALDH1A1 (0.47) | KDM4ERAB9ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1622615-A4 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| EP-1622615-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004101512-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | AURKA 417/4885KDM4E 2029/4885RAB9A 2668/4885 |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | PCNA, SAMHD1, NTPCR | AURKA 417/4885KDM4E 2029/4885RAB9A 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.